Fig. 4: mRNA-LNP vaccine candidates, encoding VZV gE, induces strong antigen-specific T cell responses. | npj Vaccines

Fig. 4: mRNA-LNP vaccine candidates, encoding VZV gE, induces strong antigen-specific T cell responses.

From: Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine

Fig. 4

A, B Female C57BL/6 mice (5 animals per group) were primed with a full human dose of the live attenuated VZV vaccine (Varivax®) by subcutaneous administration. Mice were injected intramuscularly 5 μg of the mRNA-LNP vaccine candidates, expressing the three gE variants, or Shingrix® at 4 and 8 weeks post Varivax® administration. A, B Antigen-specific effector T cell responses were measured from whole blood cells collected at week 5 i.e., 1 week post 1st immunization (A) or week 9, i.e., 1 week post 2nd immunization (Busing a murine IFN-γ/IL-2 Double-Color Enzymatic ELISpot Assay. Data shown as Mean ± SEM. Y-axis in both panels, A and B, represents Spot Forming Cells (SFCs) per million peripheral blood cells. Each SFC corresponds to an effector T cell secreting either one or both cytokines in response to the gE overlapping peptides pool.

Back to article page